Shunji Takahashi
Overview
Explore the profile of Shunji Takahashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
376
Citations
4600
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pal S, Bernard-Tessier A, Grell P, Gao X, Kotecha R, Picus J, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40043000
Background: Mutations or silencing of the von Hippel Lindau (VHL) tumor suppressor gene accumulates hypoxia-inducible factors (HIFs). HIF-2α is implicated in the oncogenesis of ~50% of patients with clear cell...
2.
Ohmoto A, Kitahama K, Shigematsu Y, Hayashi N, Yonese J, Inamura K, et al.
Histol Histopathol
. 2025 Feb;
:18887.
PMID: 40013766
Neuroendocrine carcinoma (NEC) is a rare and aggressive malignancy derived from multiple body parts, with the urogenital organs being the second-largest extrapulmonary sites. The detailed mechanism of bladder NEC pathogenesis...
3.
Jang J, Roh J, Kim G, Park J, Hwang G, Park B, et al.
J Nat Prod
. 2025 Feb;
88(2):433-439.
PMID: 39902661
Two new polyketide-cyclic peptide hybrids jejupeptins A and B (), together with a known compound eurystatin B (), were isolated from a culture of sp. KCB15JA151. The chemical structures of...
4.
Nakano K, Hayashi N, Wang X, Ohmoto A, Urasaki T, Fukuda N, et al.
Cureus
. 2025 Jan;
16(12):e76149.
PMID: 39834961
Background In 2024, reimbursement for gemcitabine-docetaxel therapy (GEM-DOC; gemcitabine 900 mg/m on days 1 and 8 and docetaxel 70 mg/m on day 8 every 21 days, GEM 900-DOC 70) to...
5.
Okines A, Curigliano G, Mizuno N, Oh D, Rorive A, Soliman H, et al.
Nat Med
. 2025 Jan;
PMID: 39825152
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer....
6.
Oaknin A, Monk B, de Melo A, Kim H, Kim Y, Lisyanskaya A, et al.
Eur J Cancer
. 2025 Jan;
216:115146.
PMID: 39798514
Aim: Cemiplimab has demonstrated significantly longer survival than physician's choice of chemotherapy in patients with recurrent cervical cancer after first-line platinum-containing chemotherapy. We report the final survival analysis from the...
7.
Urasaki T, Ono M, Yamashita K, Tanizawa T, Togashi Y, Ohmoto A, et al.
Oncol Lett
. 2025 Jan;
29(3):108.
PMID: 39776650
sarcoma is rare and its clinical features remain unclear. Given the similarity in presentation, it is possible that previously reported cases of Ewing-like adamantinoma may have been sarcoma. The present...
8.
Ohmoto A, Shigematsu Y, Saito R, Dobashi A, Fujiwara Y, Togashi Y, et al.
Virchows Arch
. 2024 Dec;
PMID: 39694932
Pheochromocytoma and paraganglioma (PPGL) are rare tumors that occur in the adrenal medulla and extra-adrenal tissues, respectively. The prognosis and tumor microenvironment (TME) of pseudohypoxic PPGL as a major entity...
9.
Koga M, Fukuda A, Nojima M, Ishizaka A, Itoh T, Eguchi S, et al.
Glob Health Med
. 2024 Nov;
6(5):316-323.
PMID: 39483444
Non-acquired immunodeficiency syndrome-defining malignancies (NADMs) are the crucial cause of mortality in people living with haemophilia and human immunodeficiency virus (PLWHH). We aimed to analyse the types and characters of...
10.
Oridate N, Takahashi S, Tanaka K, Shimizu Y, Fujimoto Y, Matsumoto K, et al.
Int J Clin Oncol
. 2024 Oct;
29(12):1825-1839.
PMID: 39382718
Background: Previously reported results from phase III KEYNOTE-048 demonstrated similar or improved overall survival (OS) with pembrolizumab or pembrolizumab-chemotherapy versus cetuximab-chemotherapy (EXTREME) in Japanese patients with recurrent/metastatic head and neck...